Epstein-Barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection

Seminars in Oncology

Volumn 42, Issue 2, 2015, Pages 258-271

  Pinzone, Marilia Rita ^a   Berretta, Massimiliano ^b   Cacopardo, Bruno ^a   Nunnari, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; BLEOMYCIN; C REACTIVE PROTEIN; DAUNORUBICIN; DOXORUBICIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; ETOPOSIDE; G PROTEIN COUPLED RECEPTOR; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 6; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LOPINAVIR PLUS RITONAVIR; PACLITAXEL; PREDNISONE; PROTEIN P53; RETINOBLASTOMA PROTEIN; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VIRAL G PROTEIN COUPLED RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANGIOGENESIS; APOPTOSIS; BURKITT LYMPHOMA; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL FEATURE; CRYOTHERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INCIDENCE; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LOW LEVEL LASER THERAPY; MOLECULARLY TARGETED THERAPY; MULTICENTRIC CASTLEMAN DISEASE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOGENESIS; PLASMABLASTIC LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VIRUS LOAD; COMPLICATION; HERPES VIRUS INFECTION; NEOPLASM; VIROLOGY;

HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 84926292521     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.12.026     Document Type: Review

References (109)

1. F.J. Palella, R.K. Baker, and A.C. Moorman HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 2006 27 34
2. M. Scarpino, M.R. Pinzone, and M. Di Rosa Kidney disease in HIV-infected patients Eur Rev Med Pharmacol Sci 17 2013 2660 2667
3. M.R. Pinzone, F. Fiorica, and M. Di Rosa Non-AIDS-defining cancers among HIV-infected people Eur Rev Med Pharmacol Sci 16 2012 1377 1388
4. D. Castronuovo, B. Cacopardo, M.R. Pinzone, S. Moreno, and G. Nunnari Bone disease in the setting of HIV infection Eur Rev Med Pharmacol Sci 17 2013 2413 2419
5. L. La Ferla, M.R. Pinzone, and G. Nunnari Kaposi' s sarcoma in HIV-positive patients: the state of art in the HAART-era Eur Rev Med Pharmacol Sci 17 2013 2354 2365
6. E. Cesarman Gammaherpesviruses and lymphoproliferative disorders Annu Rev Pathol Mech Dis 9 2014 349 372
7. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study Antivir Ther 14 2009 1065 1074
8. E.P. Simard, R.M. Pfeiffer, and E.A. Engels Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States Cancer 117 2011 1089 1096
9. Z. Grossman, J. Iscovich, and F. Schwartz Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8 Mayo Clin Proc 77 2002 905 909
10. D. Ablashi, L. Chatlynne, and H. Cooper Seroprevalence of human herpesvirus-8 (HHV-8) in countries of southeast Asia compared to the USA, the Caribbean and Africa Br J Cancer 81 1999 893 897
11. S. Mohanna, V. Maco, F. Bravo, and E. Gotuzzo Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease Int J Infect Dis 9 2005 239 250
12. S. de Sanjose, G. Mbisa, and S. Perez-Alvarez Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission J Infect Dis 199 2009 1449 1456
13. J.N. Martin, D.E. Ganem, D.H. Osmond, K.A. Page-Shafer, D. Macrae, and D.H. Kedes Sexual transmission and the natural history of human herpesvirus 8 infection N Engl J Med 338 1998 948 954
14. N.A. Smith, C.A. Sabin, and R. Gopal Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex J Infect Dis 180 1999 600 606
15. E. Martro, A. Esteve, and T.F. Schulz Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study Int J Cancer 120 2007 1129 1135
16. C. Casper, E. Krantz, and S. Selke Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men J Infect Dis 195 2007 30 36
17. J.N. Martin, and D.H. Osmond Invited commentary: determining specific sexual practices associated with human herpesvirus 8 transmission Am J Epidemiol 151 2000 225 229
18. M.A. Eltom, S.M. Mbulaiteye, A.J. Dada, D. Whitby, and R.J. Biggar Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria AIDS 16 2002 2473 2478
19. W. Klaskala, B.P. Brayfield, and C. Kankasa Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia J Med Virol 75 2005 93 100
20. B.I. Malope, P. MacPhail, and G. Mbisa No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population AIDS 22 2008 519 526
21. T.B. Campbell, M. Borok, and B. Ndemera Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe Clin Infect Dis 48 2009 1601 1608
22. W. Hladik, S.C. Dollard, and J. Mermin Transmission of human herpesvirus 8 by blood transfusion N Engl J Med 355 2006 1331 1338
23. M. Luppi, P. Barozzi, and G. Santagostino Molecular evidence of organ-related transmission of kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients Blood 96 2000 3279 3281
24. N. Dukers, and G. Rezza Human herpesvirus 8 epidemiology: what we do and do not know AIDS 17 2003 1717 1730
25. International Collaboration on HIV and Cancer Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults J Natl Cancer Inst 92 2000 1823 1830
26. Y. Chang, E. Cesarman, and M.S. Pessin Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma Science 266 1994 1865 1869
27. A.E. Grulich, Y. Li, A.M. McDonald, P.K. Correll, M.G. Law, and J.M. Kaldor Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy AIDS 15 2001 629 633
28. S. Franceschi, L.D. Maso, and M. Rickenbach Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy Br J Cancer 99 2008 800 804
29. S.E. Krown, M.A. Testa, and J. Huang AIDS related Kaposi's sarcoma: prospective validation of the AIDS Clinical trials Group staging classification J Clin Oncol 15 1997 3085 3092
30. G. Nasti, R. Talamini, A. Antinori GICAT and ICONA Study Groups AIDS-related Kaposi's sarcoma in 211 patients: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group staging system in the HAART era J Clin Oncol 21 2003 2876 2882
31. J. Stebbing, A. Sanitt, M. Nelson, T. Powles, B. Gazzard, and M. Bower A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy Lancet 367 2006 1495 1502
32. A. Viejo-Borbolla, C. Henke-Gendo, and T.F. Schulz Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) A.J. Zuckerman, J.E. Banatvala, J.R. Pattison, P.D. Griffiths, B.D. Schoub, Principles and practice of clinical virology 5th ed 2004 Wiley New York 169 198
33. B. Ensoli, S. Nakamura, and S.Z. Salahuddin AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects Science 243 1989 223 226
34. S. Nakamura, K. Murakami-Mori, N. Rao, H.A. Weich, and B. Rajeev Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells J Immunol 158 1997 4992 5001
35. R. Masood, J. Cai, T. Zheng, D.L. Smith, Y. Naidu, and P.S. Gill Vascular endothelial growth factor/ vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma Proc Natl Acad Sci U S A 94 1997 979 984
36. L.F. Brown, K. Tognazzi, H.F. Dvorak, and T.J. Harrist Strong expression of kinase insert domaincontaining receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma Am J Pathol 148 1996 1065 1074
37. Z.Y. Liu, R.K. Ganju, and J.F. Wang Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells J Clin Invest 99 1997 1798 1804
38. M. Skobe, L.F. Brown, and K. Tognazzi Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma J Invest Dermatol 113 1999 1047 1053
39. T.S. Uldrick, and D. Whitby Update on KSHV-epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma Cancer Lett 305 2011 150 162
40. R.J. Biggar, E.A. Engels, and S. Ly Survival after cancer diagnosis in persons with AIDS J Acquir Immune Defic Syndr 39 2005 293 299
41. S.E. Krown Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma J Clin Oncol 22 2004 399 402
42. M. Bower, J. Weir, and N. Francis The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma AIDS 23 2009 1701 1706
43. T. Maurer, M. Ponte, and K. Leslie HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load N Engl J Med 357 2007 1352 1353
44. C. Sgadari, G. Barillari, and E. Toschi HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma Nat Med 8 2002 225 232
45. S. Portsmouth, J. Stebbing, and J. Gill A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma AIDS 17 2003 F17 F22
46. V. Martinez, E. Caumes, and L. Gambotti Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy Br J Cancer 94 2006 1000 1006
47. M. Bower, P. Fox, K. Fife, J. Gill, M. Nelson, and B. Gazzard Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma AIDS 13 1999 2105 2111
48. P.S. Gill, J. Wernz, and D.T. Scadden Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J Clin Oncol 14 1996 2353 2364
49. D.W. Northfelt, B.J. Dezube, and J.A. Thommes Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J Clin Oncol 16 1998 2445 2451
50. D. Osoba, D.W. Northfelt, D.W. Budd, and D. Himmelberger Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine Cancer Invest 19 2001 573 580
51. L. Welles, M.W. Saville, and J. Lietzau Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma J Clin Oncol 16 1998 1112 1121
52. P.S. Gill, A. Tulpule, and B.M. Espina Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma J Clin Oncol 17 1999 1876 1883
53. M. Cianfrocca, S. Lee, and J. Von Roenn Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer 116 2010 3969 3977
54. A. Mosam, F. Shaik, and T.S. Uldrick A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa J Acquir Immune Defic Syndr 60 2012 150 157
55. R.J. Sullivan, and L. Pantanowitz New drug targets in Kaposi sarcoma Expert Opin Ther Targets 14 2010 1355 1366
56. G. Boivin, A. Gaudreau, and E. Toma Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy Antimicrob Agents Chemother 43 1999 377 380
57. R.F. Little, F. Mercad-Galindez, and K. Staskus A pilot study of cidofovir in patients with Kaposi sarcoma J Infec Dis 187 2003 149 153
58. A. Mocroft, M. Youle, B. Gazzard, J. Morcinek, R. Halai, and A.N. Phillips Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group AIDS 10 1996 1101 1105
59. D.F. Martin, B.D. Kuppermann, R.A. Wolitz, A.G. Palestine, H. Li, and C.A. Robinson Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant N Engl J Med 340 1999 1063 1070
60. F. Bihl, A. Mosam, and L.N. Henry Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma AIDS 21 2007 1245 1252
61. R.G. Nador, E. Cesarman, and A. Chadburn Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus Blood 88 1996 645 656
62. A. Carbone, and A. Gloghini PEL and HHV-8 unrelated lymphomas: classification and diagnosis Cancer 114 2008 225 227
63. A. Carbone, and A. Gloghini KSHV/HHV8-associated lymphomas Br J Haematol 140 2008 13 24
64. E.E. Mylona, I.G. Baraboutis, L.J. Lekakis, O. Georgiou, V. Papastamopoulos, and A. Skoutelis Multicentric Castleman's disease in HIV infection: a systematic review of the literature AIDS Rev 10 2008 25 35
65. T. Powles, J. Stebbing, and A. Bazeos The role of immune suppression and HHV-8 in the increasing incidence of HIV associated multicentric Castleman's disease Ann Oncol 20 2009 775 779
66. E. Oksenhendler, G. Carcelain, and Y. Aoki High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients Blood 96 2000 2069 2073
67. L. Gerard, A. Berezne, and L. Galicier Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial J Clin Oncol 25 2007 3350 3356
68. M. Bower, T. Powles, and S. Williams Brief communication: rituximab in HIV-associated multicentric Castleman disease Ann Intern Med 147 2007 836 839
69. M.R. Petrara, R. Freguja, K. Gianesin, M. Zanchetta, and A. De Rossi Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiencyvirus type 1 infection Front Microbiol 4 2013 311
70. B. He, X. Qiao, and P.J. Klasse HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors J Immunol 176 2006 3931 3941
71. P. Rieckmann, G. Poli, C.H. Fox, J.H. Kehrl, and A.S. Fauci Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors J Immunol 147 1991 2922 2927
72. S. Swingler, J. Zhou, and C. Swingler Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS Cell Host Microbe 4 2008 63 76
73. E. Colombrino, E. Rossi, and G. Ballon Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells Exp Cell Res 295 2004 539 548
74. M.R. Pinzone, B.M. Celesia, M. Di Rosa, B. Cacopardo, and G. Nunnari Microbial translocation in chronic liver diseases Int J Microbiol 2012 2012 694629
75. M.A. Marks, C.S. Rabkin, and E.A. Engels Markers of microbial translocation and risk of AIDS-related lymphoma AIDS 27 2013 469 474
76. E. Righetti, G. Ballon, and L. Ometto Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy AIDS 16 2002 63 73
77. M.R. Petrara, A.M. Cattelan, and M. Zanchetta Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients J Clin Virol 53 2012 195 200
78. M.R. Pinzone, M. Di Rosa, B. Cacopardo, and G.HIV Nunnari RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012 2012 515962
79. L.D. Kaplan, J.Y. Lee, and R.F. Ambinder Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood 106 2005 1538 1543
80. F. Boue, J. Gabarre, and C. Gisselbrecht Phase II trial of CHOP plus rituximab in patients with HIV-associated non-hodgkins lymphoma J Clin Oncol 24 2008 4123 4128
81. J.A. Sparano, J.Y. Lee, and L.D. Kaplan Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma Blood 115 2010 3008 3016
82. J.M. Ribera, A. Oriol, and M. Morgades Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial Br J Haematol 140 2008 411 419
83. J.L. Diez-Martin, P. Balsalobre, and A. Re Comparable survival between HIV+and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation Blood 113 2009 6011 6014
84. N. Mounier, M. Spina, and J. Gabarre AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood 107 2006 3832 3840
85. L. Kaplan, J. Kahn, and S. Crowe Clinical and virologic effects of recombinant human granulocyte-macrophage colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial J Clin Oncol 9 1991 929 940
86. V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, and M. Pfreundschuh CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood 113 2009 3896 3902
87. J.S. Abramson, M. Hellmann, and J.A. Barnes Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma Cancer 116 2010 4283 4290
88. L.E. Raez, P. Patel, L. Feun, A. Restrepo, W.A. Raub Jr, and P.A. Cassileth Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) Crit Rev Oncog 9 1998 199 208
89. S. Ciricillo, and M. Rosenblum Use of CT and MRI imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients J Neurosurg 73 1990 720 724
90. A. De Luca, A. Antinori, and A. Cingolani Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma Br J Haematol 90 1995 844 849
91. A. Cingolani, A. De Luca, and L.M. Larocca Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma J Natl Cancer Inst 90 1998 364 369
92. C. Corcoran, K. Rebe, H. van der Plas, L. Myer, and D.R. Hardie The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons J Clin Virol 42 2008 433 436
93. J. Baumgartner, J. Rachlin, and J. Beckstead Primary central nervous system lymphomas: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome J Neurosurg 73 1990 206 211
94. C. Jacomet, P. Girard, M. Lebrette, V.L. Farese, L. Monfort, and W. Rozenbaum Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS AIDS 11 1997 1725 1730
95. E.M. Molyneux, R. Rochford, and B. Griffin Burkitt's lymphoma Lancet 379 2012 1234 1244
96. B. Xicoy, J.M. Ribera, and M. Müller Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients Leuk Lymphoma 55 2014 2341 2348
97. L. Galicier, C. Fieschi, and R. Borie Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood 110 2007 2846 2854
98. K. Dunleavy, S. Pittaluga, and M. Shovlin Low-intensity therapy in adults with Burkitt's lymphoma N Engl J Med 369 2013 1915 1925
99. H. Delecluse, I. Anagnostopoulos, F. Dallenbach, M. Hummel, T. Marafioti, and U. Schneider Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection Blood 89 1997 1413 1420
100. J. Castillo, L. Pantanowitz, and B.J. Dezube HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases Am J Hematol 83 2008 804 809
101. J.J. Castillo, E.S. Winer, and D. Stachurski Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma Oncologist 15 2010 293 299
102. J.J. Castillo, M. Furman, and B.E. Beltrán Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy Cancer 118 2012 5270 5277
103. J. Bohlius, K. Schmidlin, and F. Boué HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+T-cell lymphocytes Blood 117 2011 6100 6108
104. R.J. Biggar, E.S. Jaffe, J.J. Goedert, A. Chaturvedi, R. Pfeiffer, and E.A. Engels Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood 108 2006 3786 3791
105. B.F. Skinnider, and T.W. Mak The role of cytokines in classical Hodgkin lymphoma Blood 101 2003 4283 4297
106. M. Serrano, C. Bellas, and E. Campo Hodgkin's disease in patients with antibodies to human immunodeficiency virus: a study of 22 patients Cancer 65 1990 2248 2254
107. B. Xicoy, J.M. Ribera, and P. Miralles Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma Haematologica 92 2007 191 198
108. M. Spina, J. Gabarre, and G. Rossi Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection Blood 100 2002 1984 1988
109. A. Re, M. Michieli, and S. Casari High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors Blood 114 2009 1306 1313